Pyxis Oncology, Inc. announced that its stockholders have approved an amendment to the company’s charter to double the number of authorized shares of common stock. The amendment, which was adopted at a Special Meeting held on November 13, 2026, increased the authorized shares from 190,000,000 to 380,000,000 shares. The amendment became effective immediately upon filing with the Secretary of State of Delaware.
The Special Meeting was held virtually at 10:00 a.m. Eastern Standard Time. As of the record date of October 8, 2026, there were 119,583,637 shares of common stock entitled to vote. At the start of the meeting, 84,997,679 shares were represented virtually, in person, or by proxy, establishing a quorum.
Stockholders voted on two proposals. Proposal One, which sought approval of the Authorized Share Increase, received 78,081,809 votes in favor, 6,706,849 votes against, and 209,021 abstentions.
Proposal Two, which allowed for the adjournment of the meeting to solicit additional proxies if necessary, received 78,656,545 votes in favor, 6,211,448 votes against, and 129,686 abstentions. The company noted that adjournment was unnecessary because there was a sufficient number of votes received to approve Proposal One.
